Ranpirnase
|
WikiDoc Resources for Ranpirnase |
|
Articles |
|---|
|
Most recent articles on Ranpirnase |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ranpirnase at Clinical Trials.gov Clinical Trials on Ranpirnase at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ranpirnase
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ranpirnase Discussion groups on Ranpirnase Patient Handouts on Ranpirnase Directions to Hospitals Treating Ranpirnase Risk calculators and risk factors for Ranpirnase
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ranpirnase |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ranpirnase is a ribonuclease enzyme found in the oocytes of the Northern Leopard Frog (Rana pipiens). Ranpirnase is a member of the pancreatic ribonuclease (RNase A) protein superfamily and degrades RNA substrates with a sequence preference for uracil and guanine nucleotides. Along with amphinase, another leopard frog ribonuclease, ranpirnase has been studied as a potential cancer treatment due to its unusual mechanism of cytotoxicity tested against tumor cells.[1]
Ranpirnase was originally discovered by scientists at TamirBio, a biotechnology company (formerly Alfacell Corporation), where it was tested in clinical trials under the brand name Onconase. The mechanism of action of ranpirnase tumor-selective cytotoxicity has been attributed to the RNA interference pathway, potentially through cleaving siRNA molecules;[2] to cleavage of transfer RNA;[1] and to interference with the NF-κB pathway.[3] Despite early indications of promise as a mesothelioma treatment,[4][5][6] and an orphan drug status designation from the United States Food and Drug Administration in 2007,[7] the Phase III clinical trial for this indication did not demonstrate statistical significance against primary endpoints.[8]
References
- ↑ 1.0 1.1 PMID 18673287 (PMID 18673287)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 18927512 (PMID 18927512)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 21901170 (PMID 21901170)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID
16305992 (PMID 16305992)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 11773179 (PMID 11773179)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 12860938 (PMID 12860938)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Waknine, Yael. "New FDA Orphan Drugs: Gestiva, Onconase, Aerosolized Ciprofloxacin". Medscape. Retrieved 2 February 2015.
- ↑ "Alfacell Annual Report 2009" (PDF). Retrieved 2 February 2015.